Related Experiment Video

Updated: Aug 5, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Therapy-Associated Vitiligo: Hypopigmentation Secondary to Programmed Cell Death Protein 1 Inhibitors, Interferon

Kritin K Verma1, Sreeya Reddy2, Caleb Beckham1

  • 1Dermatology, Texas Tech University Health Sciences Center, Lubbock, USA.

Cureus
|August 4, 2026
PubMed

Insights

Malignant melanoma (MM) patients on immune-modulating therapies like PD-1 inhibitors have a significantly higher risk of developing vitiligo. This suggests vitiligo may indicate antitumor immune response during melanoma treatment.

Area of Science:

  • Immunology
  • Dermatology
  • Oncology

Background:

  • Malignant melanoma (MM) originates from melanocytes, the same cells targeted in vitiligo, an autoimmune condition.
  • While an association between MM and vitiligo is suggested, the underlying mechanisms and treatment implications remain unclear.

Purpose of the Study:

  • To investigate the relationship between malignant melanoma (MM) and vitiligo incidence across various systemic therapies.
  • To determine if vitiligo occurrence is linked to specific melanoma treatment modalities, particularly immune-modulating agents.

Main Methods:

  • Utilized the TriNetX network to identify patients with MM receiving PD-1 inhibitors, IFN-α2b, BRAF/MEK inhibitors, or CTLA-4 inhibitors.
  • Propensity score matching was employed to compare MM patients with non-MM patients on the same therapies.
  • Analyzed vitiligo incidence using risk ratios (RRs) and 95% confidence intervals (CIs).

Main Results:

  • Malignant melanoma (MM) was significantly associated with increased vitiligo risk in patients treated with PD-1 inhibitors (RR: 24.84), IFN-α2b (RR: 3.10), and CTLA-4 inhibitors (RR: 32.04).
  • In the BRAF/MEK inhibitor cohort, vitiligo was exclusively observed in MM patients, precluding RR calculation.
  • Demographics were well-balanced between MM and matched non-MM cohorts.

Conclusions:

  • Malignant melanoma (MM) patients consistently showed a higher risk of developing vitiligo across multiple therapeutic classes compared to matched non-MM patients.
  • The strong association with immune-modulating therapies suggests vitiligo may serve as a marker of antitumor immune activation.
  • Findings indicate that even targeted therapies like BRAF/MEK inhibitors might influence melanocyte-directed immunity, warranting further investigation.
Keywords:
braf inhibitorsctla-4 inhibitorifn-alphamalignant melanomamek inhibitormelanoma treatmentpd-1 inhibitorstreatment-associated vitiligovitiligo

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...